Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 May;61(5):755–758. doi: 10.1038/bjc.1990.168

Tumour cell activity markers in epithelial ovarian cancer: are biochemical and cytometric indices complementary?

C W Redman 1, C Finn 1, K Ward 1, K Kelly 1, E J Buxton 1, R Varma 1, W Shortland-Webb 1, D M Luesley 1
PMCID: PMC1971612  PMID: 2159769

Abstract

Flow cytometry has enabled the objective assessment of cellular morphology and activity, which can also be biochemically evaluated by measuring products of cellular metabolism, such as cyclic 3'5' guanosine monophosphate (cGMP). Using paraffin-embedded formalin-fixed material obtained from the primary operation, an analysis of the correlation between nuclear ploidy and the proliferative index (PI) as quantified by flow cytometry with pre-treatment urinary cGMP was performed in 40 epithelial ovarian cancer (EOC) patients. The majority of the study group had advanced disease (28 FIGO III/IV) and residual disease (31). All but three (stage I) patients received single agent high dose cisplatinum as first-line therapy (100 mg m-2 x 5); in patients with evaluable disease there was a response rate of 64%. Thirty-one patients have died; the median survival of the study population being 27 months. There was a significant association between cGMP and PI. Significantly more aneuploid tumours had elevated PI values (P = 0.02). No variable predicted response. An initial univariate log rank analysis identified stage, the amount of residual disease, cGMP and PI as prognostic factors. Because of the interrelation between these and other factors and because PI did not conform to the proportional hazards model, a multivariate stepwise discriminant analysis was performed using survival at 36 months (the minimum follow-up for surviving patients) as the end-point. On the basis of this analysis, stage and residual disease were the most important prognostic factors, but cyclic GMP continued to have prognostic value even when these other factors were entered into the predictive model. However, the additional information gained has little clinical relevance.

Full text

PDF
755

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blumenfeld D., Braly P. S., Ben-Ezra J., Klevecz R. R. Tumor DNA content as a prognostic feature in advanced epithelial ovarian carcinoma. Gynecol Oncol. 1987 Jul;27(3):389–402. doi: 10.1016/0090-8258(87)90264-2. [DOI] [PubMed] [Google Scholar]
  2. Camplejohn R. S., Macartney J. C. Comparison of DNA flow cytometry from fresh and paraffin embedded samples of non-Hodgkin's lymphoma. J Clin Pathol. 1985 Oct;38(10):1096–1099. doi: 10.1136/jcp.38.10.1096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Deitch A. D., Law H., deVere White R. A stable propidium iodide staining procedure for flow cytometry. J Histochem Cytochem. 1982 Sep;30(9):967–972. doi: 10.1177/30.9.6182188. [DOI] [PubMed] [Google Scholar]
  4. Feichter G. E., Kühn W., Czernobilsky B., Müller A., Heep J., Abel U., Haag D., Kaufmann M., Rummel H. H., Kubli F. DNA flow cytometry of ovarian tumors with correlation to histopathology. Int J Gynecol Pathol. 1985;4(4):336–345. doi: 10.1097/00004347-198512000-00006. [DOI] [PubMed] [Google Scholar]
  5. Fowler W. C., Jr, Maddock M. B., Moore D. H., Haskill S. Significance of multiparameter flow cytometric analysis of ovarian cancer. Am J Obstet Gynecol. 1988 Apr;158(4):838–845. doi: 10.1016/0002-9378(88)90081-6. [DOI] [PubMed] [Google Scholar]
  6. Friedlander M. L., Hedley D. W., Taylor I. W., Russell P., Coates A. S., Tattersall M. H. Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res. 1984 Jan;44(1):397–400. [PubMed] [Google Scholar]
  7. Friedlander M. L., Taylor I. W., Russell P., Tattersall M. H. Cellular DNA content--a stable feature in epithelial ovarian cancer. Br J Cancer. 1984 Feb;49(2):173–179. doi: 10.1038/bjc.1984.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goh H. S., Jass J. R. DNA content and the adenoma-carcinoma sequence in the colorectum. J Clin Pathol. 1986 Apr;39(4):387–392. doi: 10.1136/jcp.39.4.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hedley D. W., Friedlander M. L., Taylor I. W., Rugg C. A., Musgrove E. A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem. 1983 Nov;31(11):1333–1335. doi: 10.1177/31.11.6619538. [DOI] [PubMed] [Google Scholar]
  10. Hiraoka M., Jo S., Akuta K., Nishimura Y., Takahashi M., Abe M. Radiofrequency capacitive hyperthermia for deep-seated tumors. I. Studies on thermometry. Cancer. 1987 Jul 1;60(1):121–127. doi: 10.1002/1097-0142(19870701)60:1<121::aid-cncr2820600123>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  11. Kallioniemi O. P., Punnonen R., Mattila J., Lehtinen M., Koivula T. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer. 1988 Jan 15;61(2):334–339. doi: 10.1002/1097-0142(19880115)61:2<334::aid-cncr2820610224>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  12. Luesley D. M., Blackledge G. R., Chan K. K., Newton J. R. Random urinary cyclic 3',5' guanosine monophosphate in epithelial ovarian cancer: relation to other prognostic variables and to survival. Br J Obstet Gynaecol. 1986 Apr;93(4):380–385. [PubMed] [Google Scholar]
  13. McGuire W. L., Dressler L. G. Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients. J Natl Cancer Inst. 1985 Sep;75(3):405–410. [PubMed] [Google Scholar]
  14. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Redman J. R., Petroni G. R., Saigo P. E., Geller N. L., Hakes T. B. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol. 1986 Apr;4(4):515–523. doi: 10.1200/JCO.1986.4.4.515. [DOI] [PubMed] [Google Scholar]
  16. Rodenburg C. J., Cornelisse C. J., Heintz P. A., Hermans J., Fleuren G. J. Tumor ploidy as a major prognostic factor in advanced ovarian cancer. Cancer. 1987 Jan 15;59(2):317–323. doi: 10.1002/1097-0142(19870115)59:2<317::aid-cncr2820590225>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  17. Seifert W. E., Rudland P. S. Possible involvement of cyclic GMP in growth control of cultured mouse cells. Nature. 1974 Mar 8;248(5444):138–140. doi: 10.1038/248138a0. [DOI] [PubMed] [Google Scholar]
  18. Turner G. A., Ellis R. D., Guthrie D., Latner A. L., Ross W. M., Skillen A. W. Cyclic GMP in urine to monitor the response to ovarian cancer to therapy. Br J Obstet Gynaecol. 1982 Sep;89(9):760–764. doi: 10.1111/j.1471-0528.1982.tb05105.x. [DOI] [PubMed] [Google Scholar]
  19. Weinstein Y., Chambers D. A., Bourne H. R., Melmon K. L. Cyclic GMP stimulates lymphocyte nucleic acid synthesis. Nature. 1974 Sep 27;251(5473):352–353. doi: 10.1038/251352a0. [DOI] [PubMed] [Google Scholar]
  20. Zeilig C. E., Goldberg N. D. Cell-cycle-related changes of 3':5'-cyclic GMP levels in Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1052–1056. doi: 10.1073/pnas.74.3.1052. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES